Ph 1/2 Program Initiated for Elraglusib in refractory melanoma and additional target solid tumor and heme cancers January 25, 2026
TROPION-Lung17 TROP2 Biomarker Directed Ph 3 Trial of DATROWAY® Initiated in Patients with Previously Treated Advanced Nonsquamous NSCLC January 18, 2026
Ph 3 KANDLELIT-007 Trial of Calderasib (MK-1084) + KEYTRUDA QLEX Initiated in Certain Patients With Advanced NSCLC January 11, 2026
Clinical Update provided on Ph 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety and Efficacy Data Observed in a Patient with MDS/AML January 11, 2026
Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study Completed January 11, 2026
Phase III Stage of the Ongoing Ph 2/3 Trial of Surufatinib – Camrelizumab combo for 1L Pancreatic Ductal Adenocarcinoma Initiated January 4, 2026
Pidnarulex (CX-5461) – Enhertu combo to be evaluated in Ph 1b trial in HER2-positive and HER2-low solid tumors and breast cancer patients December 30, 2025
First Patient Dosed in Ph 3 ALPACCA Trial of Firmonertinib in 1L EGFR PACC Mutant NSCLC December 30, 2025
Enrollment progress update provided on Ph 3 TERZO study of COPIKTRA (duvelisib) in adults with R/R nodal TFHL December 30, 2025
First Commercial Doses of PYLCLARI® for Patients with Prostate Cancer in Poland Announced December 30, 2025
Update Provided on Pivotal Ph 3 REGAL Trial of Galinpepimut-S (GPS) in AML; no outcome analyses performed December 30, 2025
First pancreatic cancer patient in global Ph 3 registrational trial, MAPKeeper 301, to be dosed in mid-2026 December 30, 2025
First Patient Dosed in Ph 1/2 Trial of CRN09682 for the Treatment of NETs and Other Somatostatin Receptor 2-Expressing Tumors December 9, 2025
DESTINY-Ovarian01 Ph 3 Trial of ENHERTU® Initiated as 1L Maintenance Therapy in Patients with HER2 Expressing Advanced Ovarian Cancer December 9, 2025
